These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2851465)

  • 1. [Abnormal calcium metabolism in myotonic dystrophy (II): Increased level of nephrogenous cyclic AMP and serum immunoreactive parathyroid hormone].
    Yoshida H; Kinoshita M; Oshima H; Saito E
    Nihon Naibunpi Gakkai Zasshi; 1988 Jul; 64(7):539-46. PubMed ID: 2851465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Abnormal calcium metabolism in myotonic dystrophy: increased level of serum 1,25(OH)2D concentration and augmented intestinal calcium absorption].
    Oshima H; Kinoshita M; Yoshida H; Saito E
    Nihon Naibunpi Gakkai Zasshi; 1986 Oct; 62(10):1203-11. PubMed ID: 3803629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Abnormal regulation of parathyroid hormone secretion by serum calcium level in myotonic dystrophy].
    Yoshida H
    Nihon Naibunpi Gakkai Zasshi; 1988 Jul; 64(7):547-53. PubMed ID: 3220153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperparathyroidism in patients with myotonic dystrophy.
    Yoshida H; Oshima H; Saito E; Kinoshita M
    J Clin Endocrinol Metab; 1988 Sep; 67(3):488-92. PubMed ID: 2842360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum ionized calcium, nephrogenous and total urinary cyclic AMP and urinary phosphate in normal subjects.
    Thode J; Holmegaard SN; Siggaard-Andersen O
    Scand J Clin Lab Invest; 1984 Apr; 44(2):111-8. PubMed ID: 6326252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Suppressibility of parathyroid function in primary hyperparathyroidism as estimated by nephrogenous cyclic AMP (author's transl)].
    Sohn HE; Yumita S; Unakami H; Miura R; Furukawa Y
    Nihon Naibunpi Gakkai Zasshi; 1982 Feb; 58(2):110-21. PubMed ID: 6282661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of renal parathyroid hormone receptor function in myotonic dystrophy.
    Konagaya Y; Konagaya M; Mano Y; Takayanagi T; Tomita A
    J Neurol Sci; 1985 Oct; 70(3):339-46. PubMed ID: 2997404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the intravenous administration of calcium on nephrogenous cyclic AMP: use as a parathyroid suppression test.
    Broadus AE; Deftos LJ; Bartter FC
    J Clin Endocrinol Metab; 1978 Mar; 46(3):477-87. PubMed ID: 221521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathophysiological studies in idiopathic hypercalciuria: use of an oral calcium tolerance test to characterize distinctive hypercalciuric subgroups.
    Broadus AE; Dominguez M; Bartter FC
    J Clin Endocrinol Metab; 1978 Oct; 47(4):751-60. PubMed ID: 233682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possibility of elevated parathyroid function in patients with calcium-containing nephrolithiasis as compared with normal controls.
    Kitamura T; Hirano Y; Ueda D; Niijima T
    Eur Urol; 1987; 13(1-2):90-9. PubMed ID: 3034619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrogenous cyclic adenosine monophosphate levels in normocalcemic cancer patients: its significance.
    Abramson EC; Kukreja SC; Lad TE; Shemerdiak WP; York PA
    Horm Metab Res; 1984 Apr; 16(4):204-7. PubMed ID: 6327481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nephrogenous cyclic AMP as a parathyroid function test.
    Broadus AE
    Nephron; 1979; 23(2-3):136-41. PubMed ID: 220548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maximal PTH secretory rate and set point for calcium in normal subjects and patients with primary hyperparathyroidism. In vivo studies.
    Gardin JP; Patron P; Fouqueray B; Prigent A; Paillard M
    Miner Electrolyte Metab; 1988; 14(4):221-8. PubMed ID: 2850460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of age on serum immunoreactive parathyroid hormone and its biological effects.
    Insogna KL; Lewis AM; Lipinski BA; Bryant C; Baran DT
    J Clin Endocrinol Metab; 1981 Nov; 53(5):1072-5. PubMed ID: 6270181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcium metabolism in paravertebral ligamentous ossification.
    Takuwa Y; Matsumoto T; Kurokawa T; Iizuka M; Hoshino Y; Hata K; Ogata E
    Acta Endocrinol (Copenh); 1985 Jul; 109(3):428-32. PubMed ID: 2992209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age-related changes in parathyroid hormone and parathyroid hormone action in normal humans.
    Marcus R; Madvig P; Young G
    J Clin Endocrinol Metab; 1984 Feb; 58(2):223-30. PubMed ID: 6319444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parathyroid hormone does not increase nephrogenous cyclic AMP excretion by the dog.
    Fox J; Heath H
    Endocrinology; 1980 Dec; 107(6):2124-5. PubMed ID: 6253291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urine calcium excretion, nephrogenous cyclic-adenosine monophosphate and serum parathyroid hormone levels in patients with essential hypertension.
    Papagalanis ND; Skopelitis P; Kourti A; Kostogianni G; Karabatsos A; Gennadiou M; Thomas S; Samartzis M; Mountokalakis T
    Nephron; 1991; 59(2):226-31. PubMed ID: 1659670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical changes before and during oral calcium tolerance test in calcium stone formers.
    Kitamura T; Hirano Y; Ueda D; Aso Y
    Urol Res; 1988; 16(3):149-55. PubMed ID: 2842910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible mechanism of impaired calcium and vitamin D metabolism in nephrotic rats.
    Mizokuchi M; Kubota M; Tomino Y; Koide H
    Kidney Int; 1992 Aug; 42(2):335-40. PubMed ID: 1328752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.